An interventional study of Paindrainer Care system in Persistent Pain, Pain Management and Remote Monitoring, sponsored by Lund University. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-26.
Sponsored by Lund University · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 88 studies in Chronic Pain with a site in Sweden — 30 open to participants now, 37 under way, none of them phase 3. Chronic Pain · Sweden.
Among the 88 studies in Chronic Pain with a site in Sweden, this one is the 50th largest by planned enrollment of the 65 interventional ones that give a count, is one of 9 that started in 2025, is one of 61 with no phase, reaches primary completion later than 5 of the 36 other live ones, and was the 75th registered.
3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.
Browse Chronic Pain studies →30 of the 88 studies in Chronic Pain with a site in Sweden are open now. Recruiting first, the newest first:
Skane University Hospital · Sites in Sweden
Ages 15–24
Karolinska Institutet · Sites in Sweden
Ages 18+
Skane University Hospital · Sites in Sweden
Ages 18–65
Catholic University of the Sacred Heart · Sites in Sweden, Italy
Ages 18+
Region Stockholm · Sites in Sweden
Ages 13–19
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
88 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 1 · Phase 4 1
First in 2004; this study’s year is marked. 9 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 60 across 2,388 interventional studies indexed under Chronic Pain.
Median enrollment 80 across the 65 interventional studies, 144 across the 23 observational. Of the 44 that completed or were terminated, 3 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 88 have an industry lead sponsor. The 10 most frequent:
Lund University is the lead sponsor of 234 studies on the registry; 36 are open to participants now.
Lund University has 5 studies filed under Chronic Pain — fewer than ten, so there is no comparison to draw.
11 of the studies in Chronic Pain with a site in Sweden that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06410963Örebro University, SwedenReActivate: Physiotherapist Led Intervention for A Adolescents and Young Adults With Musculoskelatal Pain | 2026-11-30 |
| NCT06981312Region StockholmInternet-Delivered Psychological Treatments for Chronic Pain in Adolescents: ACT and Pain Education. | 2026-12 |
| NCT06084390Vastra Gotaland RegionInterdisciplinary Rehabilitation for Chronic Pain in Primary Healthcare | 2026-12-31 |
| NCT06981611Karlstad UniversityVulvodynia Intervention: the Effect of Multimodal Treatment for Provoked Vulvodynia | 2026-12-31 |
| NCT07092332Region Örebro CountyYoung Vulvodynia: Effect and Efficacy of Multimodal Treatment. | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 88 studies in Chronic Pain with a site in Sweden, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Chronic pain impacts individuals, their families, and society significantly, yet specialist care resources are limited, with most patients managed in primary care. There is a need for tools that support self-management and improve resource allocation. This feasibility study evaluates the implementation of Paindrainer®, a CE-marked Class I digital tool, in primary care. Paindrainer® combines patient self-monitoring via an app with a healthcare provider portal (CARE) for remote monitoring. Using advanced neural networks, it offers personalized feedback to help patients plan and monitor daily activities and their impact on pain. The study aims to assess whether integrating this tool can enhance chronic pain management and patient quality of life.
Long-term pain causes significant suffering to the individual, their loved ones and also entails high societal costs. In specialist care, constant development is underway through the implementation of new research and clinical findings. Patients' own efforts, decisions and strategies are a central and effective part of today's pain management. The importance of strengthening communication between patient and healthcare professionals is increasingly emphasised, as well as promoting the patient's ability to self-manage their situation.
More recently, behavior-modifying techniques have been integrated as complementary measures in the treatment of chronic pain. Despite this, a challenge remains for the healthcare system to create long-term sustainable outcomes for people with chronic pain.
The proportion of people with long-term pain who currently receive treatment in specialist care is very small, and the majority are treated in primary care instead. Resources for this patient group are insufficient and there is a great need for new tools for self- and remote monitoring that could improve the allocation of resources for this group.
This feasibility study aims to investigate whether a digital remote monitoring tool, Paindrainer®, can be implemented in primary care. The tool contains two parts, an app for the patient to use for their own monitoring of activity levels and symptoms, and the CARE portal, which is a remote monitoring tool for healthcare. The study will further explore how the implementation of this digital app in the existing treatment strategy can help address these challenges and improve care for people with chronic pain.
Paindrainer® is a CE marked class 1 product according to MDR and is based on advanced neural networks, which enables sophisticated calculations and takes into account more variables that affect the individual's pain experience and function than the human brain can handle. By using advanced calculations, Paindrainer provides continuous feedback to the patient, giving them a tool to plan and monitor their activities and understand how they affect each other.
This study will further investigate how Paindrainer® can support the individual to plan their activities in both "necessary" areas (such as daily chores, work, sleep) and other areas that are valuable to the individual (e.g. extracurricular activities, social and physical activities). By strengthening the patient's own role, Paindrainer is expected to increase the individual's quality of life and perceived health in both the short and long term.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Has pain that affects daily life and has lasted for more than 3 months
Is over 18 years old
Understands Swedish or English
Is motivated and willing to use a digital tool for self-monitoring of activity level and symptoms
Has no planned surgeries during the study period
Has knowledge of and access to using a smartphone or tablet
Exclusion Criteria:
Severe or acute mental illness, severe anxiety, or depression
Ongoing history of substance use disorder
Serious illness under active treatment
Pain related to
Currently involved in legal proceedings or ongoing litigation related to low back or neck pain
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will use the Paindrainer® digital tool as part of their pain management strategy in primary care. Paindrainer® consists of a mobile app for self-monitoring of activity levels and symptoms, and a CARE portal for healthcare providers to support remote monitoring. The tool uses advanced neural networks to provide personalized feedback to help individuals plan and balance daily activities, aiming to enhance self-management and patient-provider communication. Standard care in primary care will continue in parallel. The study will evaluate the feasibility of implementing Paindrainer® in primary care settings and its potential to support long-term management of persistent pain conditions.
Device: Paindrainer Care system
Self management digital tool for chronic pain
Evaluation of a Digital Self-Management Tool to Support Primary Care in Managing Persistent Pain
Through the use of logged daily activities the overall purpose of this study is to investigate how the digital tool Paindrainer® can support primary care in assisting individuals with persistent pain, reducing the impact of pain in daily life, and improving quality of life. The study focuses on evaluating the effectiveness and usability of Paindrainer® in supporting primary care efforts to provide adequate care, enhance continuity, and increase patient confidence in managing long-term pain conditions. The primary parameter to analyse is PROMSI Pain interference 6a and usability questioners
Time frame: 12 weeks
Change in Health-Related Quality of Life measured by the PROMIS-29 Profile
The Patient-Reported Outcomes Measurement Information System 29-Item Profile (PROMIS-29) is a validated questionnaire designed to assess multiple domains of health-related quality of life. It includes 29 items covering seven key domains: Physical Function, Anxiety, Depression, Fatigue, Sleep Disturbance, Ability to Participate in Social Roles and Activities, and Pain Interference, along with a single item for Pain Intensity. Each domain consists of four items rated on a 5-point Likert scale, except for Pain Intensity, which uses an 11-point numeric rating scale (0-10). Higher scores indicate more of the concept being measured (e.g., higher fatigue, higher social participation).
Time frame: From baseline to 12 weeks
Change in Pain Acceptance
The Chronic Pain Acceptance Questionnaire-9 (CPAQ-9) is a validated, shortened version of the original CPAQ, designed to measure an individual's acceptance of chronic pain. The CPAQ-9 assesses two key components: Activity Engagement (participation in life activities despite pain) and Pain Willingness (openness to experiencing pain without attempts to control or avoid it). The questionnaire consists of 9 items rated on a 7-point Likert scale, where higher scores indicate greater acceptance of chronic pain.
Time frame: From baseline to 12 weeks
Change in Pain Catastrophizing measured by the Pain Catastrophizing Scale (PCS)
The Pain Catastrophizing Scale (PCS) is a validated questionnaire used to assess catastrophic thinking related to pain, including elements of rumination, magnification, and feelings of helplessness. The scale consists of 13 items scored on a 5-point Likert scale. Higher scores indicate greater levels of pain catastrophizing.
Time frame: From baseline to 12 weeks
Plan to share: Yes — De-identified individual participant data (demographic information, primary and secondary outcomes) will be shared.
Supporting information: Study protocol, Clinical study report
Time frame: Data will be available starting 6 months after publication of primary results and will be accessible for 5 years thereafter.
Access criteria: Qualified researchers with an approved proposal can request access via the study sponsor. Data will be shared through a secure data sharing platform.
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Dec 2025, 7 months after the start.
Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 7 months is below that.
Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.